logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
11/17/2021 6:59:35 AM Biohaven : NURTEC ODT Approved By Kuwait Ministry Of Health For Acute Treatment Of Migraine
11/9/2021 7:49:18 AM Biohaven, Pfizer Collaborate For Commercialization Of Rimegepant Outside U.S.
10/27/2021 7:38:44 AM Biohaven Enrolls Phase 1a/1b Trial Of BHV-1100 In Combination With NK Cell Therapy For Treatment Of Multiple Myeloma
10/5/2021 7:40:29 AM Biohaven Pharma Reports $136 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q3
9/27/2021 7:34:31 AM Biohaven Says Verdiperstat Fails In Multiple System Atrophy Program
9/9/2021 7:39:41 AM Biohaven Spotlights Nurtec ODT, Dual-therapy Indicated For Both Acute And Preventive Treatment Of Migraine,
8/9/2021 7:30:21 AM Biohaven Q2 Net Loss Widens To $210.6 Mln Or $3.23/shr From $180.9 Mln Or $3.08/shr Last Year
6/17/2021 4:05:58 PM Biohaven Appoints Kishen Mehta To Board Of Directors
5/10/2021 8:11:25 AM Biohaven Pharmaceutical Q1 Net Loss $261.0 Mln Vs. Net Loss $172.9 Mln Last Year
4/13/2021 7:34:48 AM Biohaven Pharma Highlights Neuroscience Advancements With 22 Presentations
4/7/2021 7:35:54 AM Biohaven Reports $43.8 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q1
3/29/2021 7:33:29 AM Biohaven Enrolls First Patient In Phase 2/3 Trial Of Oral Zavegepant For The Preventive Treatment Of Migraine
3/15/2021 10:48:19 PM Biohaven Prices Underwritten Public Offering Of 2.69 Mln Shares At $76.00/shr
3/11/2021 7:47:38 AM Biohaven: NURTEC ODT Approved By United Arab Emirates Ministry Of Health And Prevention For Acute Treatment Of Migraine